Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer (THOR)

This study has suspended participant recruitment.
(The study is currently non-recruiting patients or new study-sites since there is a pending substantial amendment.)
Sponsor:
Collaborator:
OnkoDataMed GmbH
Information provided by (Responsible Party):
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
ClinicalTrials.gov Identifier:
NCT01985893
First received: November 10, 2013
Last updated: February 3, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: September 2019
  Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)